Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin

Insights

Acivicin and tiazofurin exhibit distinct mechanisms impacting cancer cell nucleotide pools. Acivicin depletes purine/pyrimidine precursors and all deoxynucleotides, while tiazofurin affects IMP dehydrogenase, altering nucleotide balances and deoxynucleotide levels differently.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Hepatoma 3924A cells were used to compare the mechanisms of action of acivicin and tiazofurin.
  • Drug efficacy in cancer chemotherapy relies on understanding their molecular targets and biochemical effects.

Purpose of the Study:

  • To compare the distinct mechanisms of action of acivicin and tiazofurin in hepatoma cells.
  • To identify key enzymatic and nucleotide pool targets and indicators for each drug's action.

Main Methods:

  • Assessing the impact of acivicin and tiazofurin on primary enzyme targets.
  • Evaluating changes in ribonucleotide and deoxyribonucleotide pools.
  • Measuring enzyme activities and nucleotide concentrations in hepatoma cells.

Main Results:

  • Acivicin inhibited glutamine utilization enzymes, depleting GTP, CTP, and all deoxynucleoside triphosphates (dNTPs).
  • Tiazofurin inhibited IMP dehydrogenase, increasing IMP and PRPP, depleting GDP and GTP, and altering dNTP pools (decreased dGTP, dCTP, dATP; increased dTTP).
  • Distinct nucleotide pool alterations and enzyme inhibitions served as indicators for each drug's action.

Conclusions:

  • Acivicin and tiazofurin have unique biochemical targets and indicators in cancer cells.
  • Understanding these molecular targets can help identify sensitive/resistant cancer cells.
  • This knowledge aids in optimizing drug administration for cancer treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...